Jcr Pharmaceuticals Sustainability Profile
JCR Pharmaceuticals Co., Ltd., commonly referred to as JCR Pharma, is a leading biopharmaceutical company headquartered in Japan. Established in 2003, the company has made significant strides in the development of innovative therapies, particularly in the fields of rare diseases and regenerative medicine. With a strong focus on enzyme replacement therapies and gene therapies, JCR Pharma is renowned for its unique products that address unmet medical needs. The company operates primarily in Japan, with expanding influence in international markets. Notable achievements include the successful launch of its flagship products, which have positioned JCR Pharma as a key player in the biopharmaceutical industry. Through its commitment to research and development, JCR Pharmaceuticals continues to enhance the quality of life for patients worldwide.
DitchCarbon Score
How does Jcr Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jcr Pharmaceuticals's score of 50 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jcr Pharmaceuticals's reported carbon emissions
In 2025, JCR Pharmaceuticals reported significant carbon emissions, totalling approximately 1,087,000,000 kg CO2e for Scope 1, 640,000,000 kg CO2e for Scope 2, and a substantial 2,000,000,000 kg CO2e for Scope 3 emissions. The Scope 3 emissions breakdown includes 1,019,000,000 kg CO2e from franchises, 626,000,000 kg CO2e from capital goods, and 210,000,000 kg CO2e from waste generated in operations, among other categories. In 2024, emissions were slightly lower, with Scope 1 at about 1,062,000,000 kg CO2e, Scope 2 at 627,000,000 kg CO2e, and Scope 3 emissions at approximately 1,000,000,000 kg CO2e. The 2023 data showed a total of 1,166,000,000 kg CO2e for Scope 1, 600,000,000 kg CO2e for Scope 2, and 2,000,000,000 kg CO2e for Scope 3 emissions. JCR Pharmaceuticals has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions for Scope 1 and 2 by 2030, as part of the SuMi TRUST Group Carbon Neutral Commitment announced in October 2021. The company is actively working to calculate the greenhouse gas emissions across its entire supply chain, in line with TCFD recommendations, with a focus on transparency and risk analysis related to climate change. Overall, JCR Pharmaceuticals is committed to reducing its carbon footprint and enhancing sustainability practices, reflecting a proactive approach to climate change mitigation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 4,432,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | 29,243,000 | 00,000,000 | 00,000,000 | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Jcr Pharmaceuticals's Industry?
How Carbon Intensive is Jcr Pharmaceuticals's Location?
Jcr Pharmaceuticals's Scope 3 Categories Breakdown
Jcr Pharmaceuticals's Scope 3 emissions, which increased by 8% last year and increased by approximately 3% since 2023, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 58% of total emissions under the GHG Protocol, with "Franchises" being the largest emissions source at 42% of Scope 3 emissions.
Top Scope 3 Categories
Jcr Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Jcr Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
